The Critical Path for Parkinson’s (CPP) consortium, a global public-private partnership led by Critical Path Institute (C-Path), commemorates ten years of transformative progress in accelerating therapies for Parkinson’s disease. Founded in 2015 with the vision of uniting patients, regulators, scientists, and industry, CPP has built a collaborative model that has redefined how Parkinson’s research is conducted. Over the past decade, CPP has achieved major regulatory milestones, including multiple FDA and EMA endorsements for imaging and biofluid biomarkers, launched the Integrated Parkinson’s Database with nearly 16,000 patient-level records, and developed groundbreaking tools such as digital health technologies, trial simulation models, and patient-centered endpoints.
Looking ahead, CPP’s focus remains on advancing drug development tools and amplifying the patient voice to guide meaningful progress in Parkinson’s and related neurodegenerative diseases. With the establishment of the Patient Advisory Council and continued partnerships with organizations such as The Michael J. Fox Foundation, Parkinson’s UK, and others, CPP is shaping the next generation of research through data sharing, innovation, and inclusivity. As Executive Director Dr. Diane Stephenson notes, CPP’s tenth anniversary is not just a tribute to scientific achievement—it is a testament to the power of shared purpose and the promise of a future where collaboration accelerates medical innovation.
